🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

$10 Million Bet On This Financial Services Stock? 3 Stocks Insiders Are Buying

Published 26/07/2022, 15:30
© Reuters.  $10 Million Bet On This Financial Services Stock? 3 Stocks Insiders Are Buying
BKR
-
IXIC
-

Although US stocks closed mixed on Monday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

Baker Hughes Company

  • The Trade: Baker Hughes Company (NASDAQ: BKR) Director Michael Dumais acquired a total of 10,000 shares at an average price of $24.39. To acquire these shares, it cost around $243.9 thousand.
  • What’s Happening: Baker Hughes recently reported worse-than-expected Q2 EPS and sales results.
  • What Baker Hughes Does: Baker Hughes Company, based in Houston, Texas, provides a portfolio of technologies and services to energy and industrial value chain worldwide.
Revolution Medicines
  • The Trade: Revolution Medicines, Inc. (NASDAQ: RVMD) Director Lorence H Kim acquired a total of 50,000 shares at an average price of $20.00. To acquire these shares, it cost around $1 million.
  • What’s Happening: Revolution Medicines recently announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public offering price of $20.00 per share.
  • What Revolution Medicines Does: Revolution Medicines, incorporated in 2014, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers.
Don’t forget to check out our premarket coverage here .

Also check this: These Analysts Cut Price Targets On Walmart (NYSE:WMT) Following Outlook Cut

Health Sciences Acquisitions Corporation 2

  • The Trade: Health Sciences Acquisitions Corporation 2 (NASDAQ: HSAQ) CEO Roderick Wong bought a total of 1,000,000 shares at an average price of $10.01. To acquire these shares, it cost around $10.01 million.
  • What’s Happening: The company’s stock has gained 1% since the start of the year.
  • What Health Sciences Acquisitions Corporation 2 Does: Health Sciences Acquisitions Corporation 2, based in New York, New York, intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.